JayantKumarMD

Nephrology • Albuquerque, NM

Physician

Join to view full profile

Dr. Kumar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kumar's full profile

Already have an account?

Office
3821 Masthead St Ne
Albuquerque, NM 87109
Phone+1 505-998-7400

Fax+1 505-998-7741

Summary

Dr. Jayant Kumar is a nephrologist based in Albuquerque, NM, with extensive training and experience in the field. He completed his nephrology fellowship at Stanford University and has held an academic position as an Associate Professor at the University of Arkansas For Medical Sciences College of Medicine from 2001-2008. Dr. Kumar has contributed to the medical literature with several publications, including those in the New England Journal of Medicine and American Journal of Nephrology. His research interests are reflected in clinical trials focusing on treatments for diabetes-related kidney issues and anemia in dialysis patients. Dr. Kumar is recognized as a Regional Top Doctor by Castle Connolly from 2015 to 2024.

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Nephrology, 1998 - 2001
Montefiore Medical Center/Albert Einstein College of Medicine (New Rochelle)Residency, Internal Medicine, 1993 - 1994
Nassau University Medical CenterResidency, Internal Medicine, 1992 - 1992
All India Institute of Medical SciencesClass of 1990

Certifications & Licensure

CA State Medical License 1998 - Present
NM State Medical License 2007 - 2026
AR State Medical License 1995 - 2011
American Board of Internal Medicine Nephrology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2015-2024

Clinical Trials

Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP) Start of enrollment: 2009 Apr 01
Withdrawn
Phase 3
Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor Start of enrollment: 2011 Apr 01
Completed
Phase 2
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis Start of enrollment: 2013 Sep 03
Completed
Phase 3
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa Start of enrollment: 2014 Mar 12
Completed
Phase 3
Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus Start of enrollment: 2014 Jun 01
Completed
Phase 2, Phase 3
Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus Start of enrollment: 2014 Jul 01
Completed
Phase 2
Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis Start of enrollment: 2015 Jan 15
Completed
Phase 3
Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy Start of enrollment: 2018 Feb 15
Completed
Phase 3
Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa Start of enrollment: 2019 Jan 31
Completed
Phase 2
Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria Start of enrollment: 2019 Nov 01
Not yet recruiting
Phase 4
Join now to see all

Publications & Presentations

PubMed

7 citations
A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease.
Matthew R. Weir, Pablo E. Pergola, Rajiv Agarwal, Jeffrey C. Fink, Nelson Kopyt
American Journal of Nephrology. 2017-10-30
59 citations
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus
Vandana S Mathur, Jayant Kumar, Paul W Crawford, Howard Hait, Thomas Sciascia
American Journal of Nephrology. 2017-01-01
5 citations
Potential effect of zoledronate therapy in heavy proteinuria.
Neriman Gokden, Maurizio Zangari, Elici F, Bart Barlogie, Jayant Kumar
Clinical Nephrology. 2007-04-01

Press Mentions

New Mexico Medical Society Physician Shortage SummaryFebruary 19th, 2023
COVID-19 Vaccine Trial Kicking off in ABQJanuary 29th, 2021
Trevi Therapeutics’ Data to Be Presented at the American Academy of Dermatology’s 74March 1st, 2016